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OBJECTIVES Using a prospective study design, we assessed the value of brain natriuretic peptide (BNP) to
identify patients with heart failure who have an increased risk of deterioration of their
functional status. Furthermore, we examined the relationship between BNP and various
clinical characteristics incorporated into an established survival model used for risk stratifi-
cation.
BACKGROUND Prediction of the clinical course is a crucial part of the decision-making process about the
adequate treatment strategy for patients with advanced congestive heart failure (CHF).
Although laborious, multivariable indexes have been established for risk stratification, simple
plasma BNP measurements may be as useful as prognostic indicators.
METHODS In 78 patients referred to our heart failure clinic, plasma BNP levels were compared with the
results of a multivariable prognostic model. To assess the prognostic power of BNP, the
clinical course of this cohort was monitored for a median follow-up period of 398 days.
RESULTS At study entry, plasma BNP and the heart failure survival score (HFSS) showed a significant
correlation (r  0.706). During follow-up, Kaplan-Meier estimates of freedom from
clinical events differed significantly for patients above and below the 75th percentile
concentrations of plasma BNP (p  0.0001). Changes in plasma BNP were significantly
related to changes in limitations of physical activity, as demonstrated by logistic regression
analysis (chi-square statistic  24.9, p  0.0001). Proportional hazards analysis confirmed
BNP as a powerful predictor of functional status deterioration (p  0.0001). This prognostic
information was as powerful as that derived from the multivariable HFSS.
CONCLUSIONS Measurement of plasma BNP concentrations might provide a useful and cost-effective
screening tool that helps reduce the need and frequency for more expensive cardiac
tests. (J Am Coll Cardiol 2001;38:1934–41) © 2001 by the American College of
Cardiology
Congestive heart failure (CHF) constitutes one of the major
causes of morbidity and mortality in western countries.
Although general measures and combination pharmaco-
therapy adequately control mild and moderate stages of the
disease, heart transplantation has been established as an
important therapeutic option for patients with refractory
heart failure. With an increasing imbalance between pa-
tients placed on transplant waiting lists and the limited
supply of adequate donor organs, accurate risk stratification
that allows comparative prognostic evaluation has become a
critical component in the therapeutic approach to patients
with advanced forms of CHF. Several algorithms incorpo-
rating various hemodynamic variables or symptomatic in-
dexes have been developed in an attempt to assess an
individual’s prognosis (1–7). However, potentially due to
the heterogeneous etiology of different forms of heart
failure, most of these single-variable markers were charac-
terized by an often-unsatisfactory discrimination of patients
with and without increased heart failure mortality risk (8).
Furthermore, as most of these decision strategies depended
on invasive testing, they did not prove to be practicable for
the management of ambulatory patients. Recently, the
clinical approach to risk stratification has been substantially
improved by the development of a prospectively validated,
clinical index incorporating multiple, independent predic-
tors of mortality (9). This model effectively combined
improved sensitivity and specificity, with the advantage of a
clinical index based solely on clinical data collected nonin-
vasively. However, the routine prognostic evaluation of
ambulatory patients with advanced heart failure remains to
be limited by the need for multiple, expensive tests not
routinely applicable to a single outpatient visit.
Recently, measurement of plasma brain natriuretic pep-
tide (BNP) levels has been suggested as a cost-effective
method of screening for left ventricular (LV) dysfunction
(10,11). In the pathophysiology of CHF, BNP participates
in adaptive responses to hemodynamic alterations of heart
failure. Activation of BNP in patients with LV dysfunction
has generated considerable interest in its diagnostic and
prognostic properties. Although it is now well established
that circulating BNP levels are increased in patients with
chronic heart failure in proportion to the severity of the
disease (12–14), plasma BNP may be even more useful as a
prognostic indicator. Therefore, we hypothesized that single
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plasma BNP measurements might represent a clinically
useful screening tool to identify patients who need more
extensive risk stratification. So far, most of the information
on BNP as a prognostic marker is available in patients who
have had a myocardial infarction (15–17). Recently, addi-
tional evidence was provided by a comparison of BNP levels
in survivors and nonsurvivors of CHF (14). However, its
value in risk stratification of patients with CHF, indepen-
dent of the cause of the disease, as well as its prognostic
value regarding the clinical course of the disease (deteriora-
tion of functional status), has not been studied yet.
The objective of the present study was to assess the
prognostic value of plasma BNP measurements in ambula-
tory patients with CHF. In 78 patients referred to our heart
failure outpatient clinic, we first compared plasma BNP
measurements with the results of a well-established multi-
variable prognostic model developed by Aaronson et al. (9).
To prospectively validate the prognostic information pro-
vided by plasma BNP measurements about survival, without
clinical deterioration, we followed this cohort for a median
follow-up period of 398 days.
METHODS
Study patients. Our study group consisted of 78 ambula-
tory patients with chronic CHF, referred to our heart failure
outpatient clinic between January 1999 and July 1999.
Patients were included after optimization of medical ther-
apy. Of these patients, 89.7% were receiving angiotensin-
converting enzyme inhibitors (captopril [n  28], mean
daily dose 59  9 mg; enalapril [n  18], 15  4 mg;
ramipril [n 22], 7 3 mg) or an angiotensin II antagonist
(lorsartan [n  2], 50 mg). A total of 79.5% of the patients
were receiving beta-blockers (carvedilol [n  30], 39 
9 mg; metoprolol [n  20], 104  14 mg; bisoprolol [n 
12], 7  3 mg). The demographic and initial clinical
characteristics of these patients are listed in Table 1. On
study entry, a clinical history and physical examination,
electrocardiogram, echocardiogram, laboratory results and
cardiopulmonary exercise results were obtained in all pa-
tients. Thereafter, the patients were seen at least every three
months until death, heart transplantation or study termina-
tion. The median follow-up period was 398 days (range 248
to 493). During each follow-up visit, changes in the degree
of cardiovascular disability were assessed by taking the
patient’s history (using a standardized questionnaire assess-
ing the maximal walking distance required to produce
shortness of breath, number of stairs climbed until shortness
of breath, orthopnea [degrees of elevation of the bed at head
level, number of pillows] and nocturia [number of events])
and performing a physical examination (changes in pulmo-
nary rales, jugular venous distention, hepatic enlargement or
peripheral edema). Although there is a high variability
between different individuals, follow-up of this information
over time has been shown to provide a subtle measure of
changes within the same individual (good intra-individual
reproducibility). Changes in the patient’s degree of cardio-
vascular disability over time were categorized as an “im-
provement,” “stabilization” or “deterioration.” A patient’s
death due to a cardiovascular cause was categorized as
deterioration. For patients who remained alive and non-
transplanted, follow-up was discontinued on June 30, 2000.
Measurement of plasma BNP concentrations. Brain na-
triuretic peptide was measured once, on study entry. Blood
samples were collected in ethylenediaminetetraacetic acid
after at least 20 min of supine rest, immediately placed on
ice and centrifuged within 60 min. The plasma fraction was
stored at 70°C until analysis. Plasma BNP concentrations
were measured using a specific immunoradiometric assay
that detects the biologically active 32–amino acid peptide
(Shionoria BNP kit, CIS Bio International, Gifsur-Yvette,
France), as described previously (12). This assay uses two
monoclonal antibodies against human BNP—one recogniz-
ing a carboxy-terminal sequence and the other recognizing
the ring structure of human BNP. In our study, the
interassay coefficient of variation (n  18) of the assay was
7% at a mean concentration of 19.7 pg/ml and 5% at 291
pg/ml. Cross-reactivity for atrial natriuretic peptide was
specified by the manufacturer as 0.001%.
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  congestive heart failure
HFSS  heart failure survival score
LV  left ventricular
NYHA  New York Heart Association
UNOS  United Network for Organ Sharing
·VO2max  maximal oxygen consumption
Table 1. Characteristics of the Patient Group (n  78)
Age years 51  9 (24–65)
Male gender 69 (88.5%)
NYHA functional class
I 10 (12.8%)
II 33 (42.3%)
III 26 (33.3%)
IV 9 (11.5%)
Ischemic cardiomyopathy 24 (30.8%)
Rest heart rate (beats/min) 77  15 (44–110)
Mean blood pressure (mm Hg) 88  13 (62–123)
LV ejection fraction (%) 36  15 (10–59)
Mean PCWP (mm Hg) 15  9 (2–44)
Peak V˙o2 ml/kg (per min) 15  4 (5–25)
Serum sodium (mmol/l) 137  4 (124–147)
IVCD 44 (56.4%)
Medical therapy
Diuretics 75 (96.2%)
ACE inhibitors, AT-II antagonists 70 (89.7%)
Beta-blockers 62 (79.5%)
Aldosterone antagonists 28 (35.9%)
Digitalis 64 (82.1%)
Data are expressed as the mean value SD (range) for continuous variables and as the
number % of patients for dichotomous variables.
ACE  angiotensin-converting enzyme; AT  angiotensin; IVCD  intraven-
tricular conduction delay; LV  left ventricular; NYHA  New York Heart
Association; PCWP  pulmonary capillary wedge pressure; V˙o2  oxygen consump-
tion.
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Hemodynamic measurements. The mean blood pressure
at rest was estimated as diastolic pressure plus one-third of
the pulse pressure measured after at least 20 min of supine
rest. The rest heart rate was obtained from a standard
12-lead electrocardiogram. The LV ejection fraction was
estimated by echocardiography, using the Simpson’s rule
(18). Maximal oxygen consumption (·VO2max) was mea-
sured using an incrementally progressive, symptom-limited
cardiopulmonary exercise test, as described previously (19).
Risk stratification. For each patient, a prognostic score
was derived by using an established, prospectively validated
model incorporating multiple, independent predictors of
CHF mortality (9). In this model, an individual prognostic
score (heart failure survival score [HFSS]) was calculated as
the absolute value of the sum of the products of the
identified prognostic variables and their computed coeffi-
cients. As explanatory variables (model coefficients), this
model includes the presence or absence of ischemic cardio-
myopathy (0.6931), rest heart rate (0.0216), LV ejec-
tion fraction (0.0464), mean blood pressure (0.0255), pres-
ence or absence of an intraventricular conduction delay
120 ms (0.6083), ·VO2max (0.0546) and serum sodium
(0.0470). The resultant HFSS was used to assign the
individual patients to one of three prognostic score risk
groups—low risk: HFSS 8.10; medium risk: HFSS 7.20
to 8.09; and high risk: HFSS7.20. These prognostic score
risk groups have been shown to effectively stratify the risk of
death or need for urgent transplantation (one-year event-
free survival rates—low risk: 93  2%; medium risk: 72 
5%; and high risk: 43  7%).
Statistics. Correlation values were estimated to indicate
the relationship between the plasma BNP concentration
and HFSS. To determine whether the correlation coeffi-
cient is significantly different from zero, the Fisher r to z
transformation was carried out. Analysis of variance was
used to compare plasma BNP concentrations between
patients in different New York Heart Association (NYHA)
functional classes or HFSS risk strata. Post-hoc testing was
performed using the Bonferroni/Dunn procedure. A p value
0.05 was considered significant.
Analysis of variance was used to compare plasma BNP
concentrations in patients with different clinical outcomes.
The ability of the plasma BNP concentration to predict the
clinical outcome after 12 months was assessed by logistic
regression analysis of polytomographic measurements. The
prognostic value of plasma BNP concentrations was tested
using a proportional hazards regression model. The Kaplan-
Meier method and the log-rank test were used to evaluate
differences in freedom from clinical deterioration among
patients with high and low plasma BNP concentrations.
The ability of plasma BNP concentrations and HFSS to
identify patients who will experience clinical deterioration
was compared by receiver-operating characteristics analysis.
All data are presented as the mean value  SEM.
Statistical analysis was performed using StatView, version
5.0 (SAS Institute, Cary, North Carolina).
RESULTS
Comparison of plasma BNP with multivariate risk strati-
fication. Plasma BNP concentrations measured at the time
of study entry ranged from 5.4 to 686.0 pg/ml (median
105). In 72 patients (92.3%), the plasma BNP concentration
was detected above the normal range (18 pg/ml). Plasma
levels of BNP increased significantly according to different
NYHA functional classes (class I: 21.6 2.8 pg/ml; class II:
108.6 16.3 pg/ml; class III: 197.1 27.2 pg/ml; class IV:
363.0  67.8 pg/ml; p  0.0001). Plasma BNP levels did
not differ between patients with ischemic (150.6  25.7
pg/ml; n  24) and those with nonischemic cardiomyopa-
thy (158.9  22.2 pg/ml; n  54).
By use of an established risk-stratification model, a
prognostic score—the HFSS—was derived for each patient
at the time of BNP measurement. The HFSS ranged from
6.25 to 12.62 (median 8.95). Based on these scores, patients
were classified into three different prognostic score risk
groups. Ten patients (12.8%) were assigned to the low-risk
group; 58 patients (74.4%) to the medium-risk group; and
10 patients (12.8%) to the high-risk group.
As depicted in Figure 1, plasma BNP concentrations and
HFSS showed a significant inverse correlation (r0.706,
p 0.0001). A high prognostic HFSS, indicating a low risk
of an adverse outcome, was related with low plasma BNP
levels, whereas a low HFSS indicated high plasma BNP
levels. As shown in Figure 2, this resulted in significant
differences in the three different HFSS prognostic risk
groups with different mean plasma BNP concentrations
(low-risk group: 95.7  11.2 pg/ml; medium-risk group:
244.4  33.4 pg/ml; and high-risk group: 419.9  55.5
pg/ml; p  0.0001).
Prospective validation of the prognostic value of BNP. No
patient was lost to follow-up. During follow-up, six patients
(7.7%) died of a cardiovascular cause (median 6 months
after study entry [range 4 to 11]). Seven patients (9.0%)
required urgent United Network for Organ Sharing
(UNOS)-1 transplantation (median 9 months after study
entry [range 3 to 10]). Six patients (7.7%) underwent
UNOS-2 transplantation, without a deterioration of their
clinical status before transplantation (median 13 months
after study entry [range 6 to 16]). For the Kaplan-Meier
analysis, survival data on those patients undergoing
UNOS-2 transplantation without previous clinical worsen-
ing were censored at the time point of transplantation.
Fifty-nine patients remained alive and nontransplanted, 34
of whom (57.6%) did not experience any change in limita-
tion of physical activity (classified as “stabilization”). Thir-
teen patients (22%) reported improved physical activity
(classified as “improvement”). In 12 patients (20.3%), a
decrease in physical activity was observed (classified as
“deterioration”). As shown in Figure 3, the initial plasma
BNP concentration differed between these groups (im-
provement group: 42.4  8.6 pg/ml; stabilization group:
102.2  16.1 pg/ml; and deterioration group: 256.9 
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28.5 pg/ml; p  0.0001). When examining the overall
relationship between changes in cardiovascular disability (as
the dependent variable) with plasma BNP levels (as the
independent variable), logistic regression analysis showed
that changes in plasma BNP were significantly related to
changes in limitations of physical activity (likelihood ratio/
chi-square statistic  24.9, p  0.0001). Pairwise compar-
isons demonstrated that increased plasma BNP levels were
strongly associated with a deterioration of physical activity
(p  0.003). However, lower plasma BNP levels only
showed a modest association with improvement of physical
activity (p  0.42).
Kaplan-Meier estimates of freedom from clinical events
Figure 1. Relationship between brain natriuretic peptide (BNP) plasma concentrations and heart failure survival score (HFSS) in 78 patients. A high HFSS,
indicating a low risk of an adverse outcome, was related to low plasma BNP levels, whereas a low HFSS indicated high plasma BNP levels.
Figure 2. Comparison of brain natriuretic peptide (BNP) plasma concen-
trations in patients assigned to the three distinct prognostic score risk
groups according to their heart failure survival score (HFSS) (low risk:
HFSS 8.10, n  58; medium risk: HFSS 7.20 to 8.09, n  10; and high
risk: HFSS7.20, n 10). Data are presented as the mean value SEM.
Figure 3. Comparison of brain natriuretic peptide (BNP) plasma concen-
trations in patients according to their development of cardiovascular
function after 12 months (improvement: n 13; stabilization: n 34; and
deterioration: n  12). Data are presented as the mean value  SEM.
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were compared for patients classified into two groups
according to the 75th percentile concentrations of plasma
BNP. Clinical events were defined as progression of a
cardiovascular disability (categorized as deterioration) or
patient death. As shown in Figure 4, the estimated
freedom from clinical events curve for patients with
plasma BNP levels below the 75th percentile (BNP
107.5 pg/ml) lies above the estimated function for
patients with high plasma BNP levels (107.5 pg/ml).
These observed differences were statistically significant
(log-rank/chi-square statistic  25.046, p  0.0001).
Univariate proportional hazards analysis showed that BNP
was a significant predictor of clinical events (deterioration of
physical activity or patient death). The relative hazards ratio for
a clinical event associated with an increase in the plasma BNP
concentration by 100 pg/ml was calculated at 1.492 (95%
confidence interval 1.221 to 1.819). However, as tested with a
multivariate regression model, BNP did not add prognostic
information independent of HFSS (p  0.748).
The ability of plasma BNP levels and HFSS to identify
the risk of a clinical event was assessed by comparison of
receiver-operating characteristic curves. As shown in Figure
5, the sensitivity and specificity of plasma BNP were
comparable to those of HFSS. With a cut-off value of
107.5 pg/ml (75th percentile), BNP was able to discrim-
inate patients with from those without clinical events,
with a sensitivity of 88% and a specificity of 75%.
DISCUSSION
In the present study, we could demonstrate that measurement
of plasma BNP provides important prognostic information on
patients with CHF, independent of the cause of the disease.
Patients with high circulating levels of BNP had a substantially
higher probability of deterioration of their functional status or
death, as compared with those with only moderately increased
levels. The prognostic information provided by this single
variable was as powerful as that derived from a commonly used,
well-established predictive model incorporating multiple clin-
ical characteristics. Hence, determination of plasma BNP
might further improve our current approach to patients with
advanced CHF by helping to identify those patients who need
more extensive risk stratification, using established multivari-
able risk-stratification models.
Pathophysiologic rationale for BNP as a potential prog-
nostic marker. Risk stratification of chronic heart failure is
confounded by several factors. First, heart failure is a
multi-system disease involving not only compromised car-
diovascular hemodynamic variables, but also altered regula-
tion of various neurohormonal reflexes and deranged func-
tion of other organ systems, such as the kidney or skeletal
muscle (20). Second, heart failure mortality is not just
caused by mechanical dysfunction of the heart. Further-
more, several trials have suggested that up to 50% of the
deaths may be related to an arrhythmic episode, rather than
hemodynamic deterioration with terminal pump failure
Figure 4. Kaplan-Meier estimates of freedom from clinical deterioration or death in patients stratified into two groups according to the 75th percentile of
all plasma brain natriuretic peptide (BNP) concentrations.
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(21,22). Hence, it does not seem surprising that single
hemodynamic markers may help to assess the current
severity of the disease; however, they do not provide
sufficient information on the patient’s future prognosis. In
marked contrast, the level of natriuretic peptides has been
suggested to not only indicate the severity of the disease, but
also reflect the physiologic attempt to compensate for the
pathophysiologic sequelae of heart failure and reconstitute
circulatory homeostasis (23). Its functional properties might
be expected to influence both mechanical dysfunction and
arrhythmic instability as the major mechanisms of heart
failure mortality. Besides its beneficial effects on systemic
vascular resistance and cardiac output, the ability of the
cardiac natriuretic peptides to limit the release of cat-
echolamines and renin might reduce the arrhythmogenic
potential of these substances. Hence, unlike hemodynamic
markers or other neurohormones, measurement of the
circulating concentration of a single natriuretic peptide
might provide information on multiple constituents of the
pathophysiology of CHF, reflecting the complex interplay
of several factors contributing to the course of the disease.
Unlike vasoconstricting neurohormones, which play a mal-
adaptive, pathogenetic role in the progression of CHF,
cardiac natriuretic peptides are believed to participate in
adaptive responses thought to limit the pathophysiologic
sequelae of heart failure. Infusion of synthetic BNP in
patients with chronic heart failure has been shown to
decrease pulmonary capillary wedge pressure, diminish sys-
temic vascular resistance and increase cardiac output (24–
26). Furthermore, administration of synthetic BNP resulted
in a rapid and sustained improvement of the patient’s
clinical status (26). These studies suggest an important
protective role of BNP in delaying the progression of CHF.
At first inspection, these beneficial effects appear to be in
contrast to the present observation that high circulating
BNP levels are predictive of clinical deterioration of the
patient’s functional status. As one possible explanation, a
dissociation of increasing BNP and unchanged levels of
its second messenger, cyclic guanosine monophosphate,
were reported in nonsurvivors of CHF, indicating a
potential relationship between increased BNP levels,
impaired BNP activity and mortality in CHF (14).
Further studies are needed to elucidate the underlying
mechanisms responsible for the progression of chronic
heart failure–associated tissue hyporesponsiveness to na-
triuretic peptides.
Potential role of BNP in risk stratification. In the present
study, levels of circulating BNP measured at study entry
were used to assess the future course of the disease. This
application as a prognostic indicator significantly extends its
current use as a diagnostic marker (10,27–29). Established
clinical models currently used for risk stratification presup-
pose assessment of multiple variables (3,9). Some of these
variables, such as cardiac output or pulmonary capillary
wedge pressure, require invasive testing. Others, such as
·VO2max, must be derived by time-consuming, noninvasive
testing. Due to the time-consuming and cost-intensive
nature of this approach, accurate identification of those
patients in need of such extensive risk stratification is
mandatory. The results of the present study suggest plasma
BNP is a helpful and cost-effective screening tool in the
clinical work-up of patients to identify those who require a
more extensive prognostic work-up using HFSS or other
risk-prediction models, in order to adequately plan future
therapeutic strategies, such as placement on a heart trans-
plant waiting list. Hence, BNP assays will not obviate the
need for multivariable and prospectively validated risk strat-
ification in those selected patients. However, measurement
of BNP could help to reduce the number of patients to be
evaluated using these multivariable models, as well as limit
the frequency for extended cardiac investigations. In a retro-
spective analysis in our patient group, optimized sensitivity of
BNP to exclude false-negative conclusions was reached
using a cut-off value of 94 pg/ml. With exclusion of
patients with renal insufficiency or suboptimal medical
therapy, this cut-off value proved to be useful in identi-
fying all patients with worsening of their functional
cardiovascular status within the follow-up period of 248
to 493 days after BNP measurement. With a specificity of
66% at this cut-off value, this subgroup of patients should
undergo further risk stratification to identify potential
candidates for placement on a heart transplant waiting
list.
Brain natriuretic peptide versus HFSS. The well-
established multivariable HFSS might be considered the
current reference standard for risk stratification of patients
with advanced CHF, to be implemented in most clinical
work-up protocols to identify potential candidates for heart
transplantation. Although in our study group, the prognos-
tic information of BNP has been shown to be comparable to
that of HFSS, to emphasize its prognostic properties, there
are some major restrictions to this comparison. Although
Figure 5. Receiver-operating characteristic curves for plasma brain natri-
uretic peptide (BNP) concentrations and heart failure survival score
(HFSS), to predict the risk of clinical deterioration or patient death.
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the major objective of the study of Aaronson et al. (9) was
to develop a model that could select candidates for heart
transplantation from an already preselected population of
patients with advanced CHF, our goal was to establish a
simple variable to be used in a nonselected, ambulatory
patient population presenting with clinical signs of heart
failure, in order to plan the future therapeutic strategy.
Therefore, the characteristics of the present study group
differed from those used to derive and validate the original
HFSS. This study evaluated a nonselected patient group
that was not as severely ill as that evaluated by Aaronson et
al. (9), as indicated by a higher mean ejection fraction and
a lower mean NHYA functional class. Besides different
entry criteria, the patient groups of these two studies also
differed with regard to the underlying medical therapy.
Although the HFSS was derived from patients recruited
before introduction of beta-blockers and aldosterone antag-
onists to the standard medical therapy of advanced CHF, in
our study group, 79.5% of all patients were receiving beta-
blockers and 35.9% were receiving spironolactone. It might be
speculated that, aside from their proven prognostic benefits,
the use of these substances may influence the resultant HFSS
by directly modulating the variables of rest heart rate, mean
blood pressure, serum sodium and intraventricular conduction
delay. Currently, several studies are under way to address the
important question of whether HFSS can be revalidated in
patients treated with an optimized combination of beta-
blockers and aldosterone antagonists.
Conclusions. Methods to detect BNP are inexpensive and
widely available. Besides its already-established diagnostic
properties, BNP as a neurohormonal prognostic marker
could reduce the need and frequency for more expensive
cardiac investigations. Of course, factors independent of LV
dysfunction also increase BNP concentrations. However,
the high negative predictive accuracy of this test still ensures
the adequate reliability of BNP levels as a screening tool.
Even with additional inducers of BNP expression, indepen-
dent of LV dysfunction, low BNP levels exclude the need
for further risk stratification. High BNP levels necessitate
further diagnostic testing and risk stratification.
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